PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025Acta Dermatovenerologica Alpina Pannonica et Adriatica2 citations

Oral lichen planus: key features of etiopathogenesis, diagnosis, and management

View Full Paper
AGAna GlavinaLZLucija ZanzeEBEma Barac

Key Points

  • Oral lichen planus is a chronic inflammatory autoimmune disease linked to genetic and environmental factors.
  • Diagnosis is based on unique histopathological features and clinical forms that vary among patients.
  • Treatment focuses on controlling inflammation and alleviating symptoms like pain and burning, with constant monitoring.
  • OLP is classified as a potentially malignant disorder, with significance placed on regular follow-ups to assess transformation risk.

Abstract

Oral lichen planus (OLP) is a chronic inflammatory autoimmune disease of unknown etiology. It is assumed that a genetic predisposition contributes to the development of the disease and influences the patient's response to various etiological factors such as autoimmune reactions to epithelial antigens, microorganisms, and stress. Immunopathogenesis is primarily driven by cell-mediated immune mechanisms, with T lymphocytes playing a central role. The clinical presentation of OLP is varied, and multiple clinical forms can occur in the same patient. OLP is categorized into six clinical types: reticular, papular, and plaque-like (hyperkeratotic variants), and atrophic, erosive, and bullous (erosive variants). The histopathological diagnosis of OLP is unique. Continuous follow-up of patients is crucial because OLP is considered an oral potentially malignant disorder (OPMD). Reported rates of malignant transformation vary, with a pooled estimate of 1.43% for OLP and 5.13% for OLP with dysplasia. Patient education plays a crucial role in treatment initiation and planning. A personalized treatment approach focuses on controlling inflammation and relieving symptoms such as pain and burning. Treatment should be individualized according to disease severity, subtype, and patient response, with constant monitoring for possible malignant transformation and comorbidities.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Glavina et al. (2025) studied this question.

synapsesocial.com/papers/68c1a26954b1d3bfb60dd838https://doi.org/10.15570/actaapa.2025.21
Ask AI
Helpful
Bookmark
Share
View Full Paper